WallStreetZenWallStreetZen

NASDAQ: NVAX
Novavax Inc Stock

$15.50+0.35 (+2.31%)
Updated May 24, 2024
NVAX Price
$15.50
Fair Value Price
N/A
Market Cap
$2.18B
52 Week Low
$3.53
52 Week High
$17.40
P/E
-4.95x
P/B
-2.51x
P/S
0.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$996.61M
Earnings
-$398.71M
Gross Margin
63%
Operating Margin
-38.27%
Profit Margin
-40%
Debt to Equity
-2.56
Operating Cash Flow
-$472M
Beta
1.11
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

NVAX Overview

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NVAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVAX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NVAX due diligence checks available for Premium users.

Be the first to know about important NVAX news, forecast changes, insider trades & much more!

NVAX News

Valuation

NVAX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.95x
Industry
15.58x
Market
32.03x

NVAX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-2.51x
Industry
6.08x

NVAX's financial health

Profit margin

Revenue
$93.9M
Net Income
-$147.6M
Profit Margin
-157.2%
NVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NVAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.4B
Liabilities
$2.2B
Debt to equity
-2.56
NVAX's short-term liabilities ($804.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVAX's long-term liabilities ($1.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$83.6M
Investing
-$7.3M
Financing
$5.9M
NVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NVAX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NVAX$2.18B+2.31%-4.95x-2.51x
RXRX$2.18B+1.44%-5.65x5.43x
CGON$2.18B+9.07%N/A3.83x
ADMA$2.22B+0.95%-478.00x14.42x
RYTM$2.24B-1.63%-7.94x36.40x

Novavax Stock FAQ

What is Novavax's quote symbol?

(NASDAQ: NVAX) Novavax trades on the NASDAQ under the ticker symbol NVAX. Novavax stock quotes can also be displayed as NASDAQ: NVAX.

If you're new to stock investing, here's how to buy Novavax stock.

What is the 52 week high and low for Novavax (NASDAQ: NVAX)?

(NASDAQ: NVAX) Novavax's 52-week high was $17.40, and its 52-week low was $3.53. It is currently -10.92% from its 52-week high and 338.84% from its 52-week low.

How much is Novavax stock worth today?

(NASDAQ: NVAX) Novavax currently has 140,403,554 outstanding shares. With Novavax stock trading at $15.50 per share, the total value of Novavax stock (market capitalization) is $2.18B.

Novavax stock was originally listed at a price of $100.00 in Dec 31, 1997. If you had invested in Novavax stock at $100.00, your return over the last 26 years would have been -84.5%, for an annualized return of -6.92% (not including any dividends or dividend reinvestments).

How much is Novavax's stock price per share?

(NASDAQ: NVAX) Novavax stock price per share is $15.50 today (as of May 24, 2024).

What is Novavax's Market Cap?

(NASDAQ: NVAX) Novavax's market cap is $2.18B, as of May 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novavax's market cap is calculated by multiplying NVAX's current stock price of $15.50 by NVAX's total outstanding shares of 140,403,554.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.